Hematologic Oncology

An expert in hematology/oncology reviews study data and results from the phase 3 REACH3 trial for steroid-refractory chronic graft-vs-host disease.

A supplemental new drug application has been submitted to the FDA for ibrutinib to help treat pediatric and adolescent patients with chronic graft versus host disease.

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.

Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.

Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, re-caps the 2021 American Society of Hematology conference and discusses which presentations were the most important.

A label update for the CAR T-cell therapy product axicabtagene ciloleucel has been approved by the FDA to allow for use of prophylactic corticosteroid to manage cytokine release syndrome.

SNIPR001 has received a fast track designation by the FDA for the prevention of blood infections in patient with hematologic malignancies.

Research from the Journal of Clinical Oncology suggests that venetoclax is a promising option for patients diagnosed with previously treated Waldenström macroglobulinemia.

At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.

Investigators believe that storing red blood cells in a hypoxic state could reduce the development of vaso-occlusion flowing transfusion.

Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.

Abatacept can now be used for the prevention of acute graft-versus-host disease following its approval by the FDA.

Depression and anxiety notably impact how patients with hematologic malignancies view clinical studies.

Investigators noted that patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were more likely to experience COVID-19 mortality vs non-cancer patients.

Orca-T improved efficacy outcomes over standard of care therapy for patients with serious hematologic malignancies.

A United States indication for duvelisib in previously treated relapsed/refractory follicular lymphoma has been voluntarily withdrawn by developer Secura Bio following an assessment of the drug and subsequent consultation with the FDA.

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

Cell therapy omidubicel, designed for patients with hematologic malignancies who are undergoing allogeneic stem cell transplant, will be submitted to the FDA for approval in 2022.

The single-cell functional precision medicine treatment, an artificial intelligence strategy helps to create therapies for patients with hematologic cancers.

Older patients undergoing treatment for B-cell malignancies who contracted the COVID-19 virus were at an increased risk of death vs patients with other cancers under the age of 60 years.

The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.